Reaction Science Consulting provides experienced technical leadership assisting a select number of small and medium-sized pharmaceutical companies with chemical manufacturing and process technology guidance as their pharmaceutical candidates approach commercialization. Reaction Science Consulting’s ideal long-term client is one seeking to bring a new therapeutic agent to market within the next several years, or to sell / license their pharmaceutical product asset to a larger company. It is also a reliable service provider for:
- Contract R&D for API manufacturing process technology and analytical methods
- Analytical studies designed to resolve CMC regulatory issues
- API impurity / API degradant isolation and structural identification
- Analytical testing and development of in-process control methods
Novatia works closely with Reaction Science Consulting on many different types of projects where their expertise in Process Chemistry, Compound Isolation, and Regulatory Compliance can be utilized to solve a customer’s problem. We offer a single point of contact on joint projects, whereby, either Novatia or Reaction Science Consulting can serve as the lead company.
Think Thermo Scientific for superior analytical instruments, laboratory equipment, software, services, consumables and reagents. Find better workflow solutions spanning sample preparation, sample analysis, and data interpretation.
Novatia uses several Thermo Scientific products in its laboratory, such as, LC/UV/MS systems, sample storage, and consumables. Additionally, Thermo Scientific mass spectrometers are a preferred component in Novatia’s Oligo HTCS System, for high-throughput / fully automated analysis of oligonucleotides.
In 1989 LEAP Technologies was formed in Carrboro, NC in order to serve automation needs in the analytical laboratory (Chromatography and Mass Spectrometry related). LEAP delivers the automation advantage to R&D, pharmaceutical, polymer, food processing, forensic, and academic laboratories.
Novatia uses many LEAP Technologies products in its laboratory, such as, autosamplers and consumables. Additionally, LEAP Technologies autosamplers are a preferred component in Novatia’s Oligo HTCS System, for high-throughput / fully automated analysis of oligonucleotides.
Michrom BioResources was incorporated in April, 1989 to provide innovative microfluidic products for life science applications. As a pioneer in the field of microscale protein and peptide separations, Michrom evolved to become a premier supplier of LCMS instruments, accessories and consumables for proteomics researchers around the world.
Novatia uses many Michrom BioResources products in its laboratory, such as, LC systems and consumables. Additionally, Michrom’s Paradigm MS4 system is a preferred component in Novatia’s Oligo HTCS System, for high-throughput / fully automated analysis of oligonucleotides.
On April 1, 2011 Bruker acquired Michrom Bioresources, Inc. Bruker intends to invest in the further development of the proprietary CaptiveSpray(TM) Ionization (CSI) sources for LC-MS, of HPLC liquid chromatography systems, and of related novel LC accessory, software and consumables products.
Magnetic Resonance Microsensors (MRM), an operating unit of Protasis Corporation, is the leading maker of capillary-based, microliter-volume probes for NMR spectroscopy. These new-to-market devices rely on microcoil technology and offer fast, sensitive performance and downscaled sample handling capability.
Novatia uses Protasis MRM’s capillary NMR probe for various studies where sample amounts are very limited. This technology has been instrumental for trace-level structure elucidation projects at Novatia.
HepatoChem’s innovative technology uses biomimetic catalysts to mimic the metabolic function of the liver. Its unique technology, developed in collaboration with John Groves’ laboratory at Princeton University, enables the production of metabolites faster and with greater cost-effectiveness than any other available technology.
Recently, Novatia needed to obtain NMR data on a metabolite observed at trace levels in a customer’s in vivo sample. Conventional incubation-based approaches, even with bioengineered enzymes, had not been able to generate the target metabolite from the customer’s compound due to its poor solubility in incubation buffers. HepatoChem generated the target metabolite for Novatia at a level sufficient for successful NMR studies.